Fig. 3From: Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panelProtocol for [TIMP-2]•[IGFBP7] testing. ACEs, angiotensin-converting enzymes; AKI, acute kidney injury; ARBs, angiotensin-receptor blockers; ICU, intensive care unit; NSAIDS, nonsteroidal anti-inflammatory drugs; UO, urinary outputBack to article page